Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10367667 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL13831932 | 0.97 | HRH3 (0.65) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL739192 | 0.92 | HRH3 (0.65) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL10369304 | 0.92 | HRH3 (0.65) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL736509 | 0.89 | — | — | |
| SCHEMBL5665906 | 0.86 | HRH3 (0.93) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9126300 | 0.83 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9371058 | 0.83 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3156252 | 0.83 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15933346 | 0.83 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20150119345-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | Lumena Pharmaceuticals, Inc. (US) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119345-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | SLC10A2, SLC10A1, NR1H4 | HRH3 590/4885MAPT 3019/4885CYP1A2 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.